DK3920970T3 - Fremgangsmåde til behandling af utilsigtede hændelser induceret af checkpoint-hæmmere - Google Patents
Fremgangsmåde til behandling af utilsigtede hændelser induceret af checkpoint-hæmmere Download PDFInfo
- Publication number
- DK3920970T3 DK3920970T3 DK20702304.5T DK20702304T DK3920970T3 DK 3920970 T3 DK3920970 T3 DK 3920970T3 DK 20702304 T DK20702304 T DK 20702304T DK 3920970 T3 DK3920970 T3 DK 3920970T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedure
- treatment
- adverse events
- checkpoint inhibitors
- events induced
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 230000002411 adverse Effects 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305128 | 2019-02-04 | ||
| PCT/EP2020/052554 WO2020161045A1 (en) | 2019-02-04 | 2020-02-03 | Method for treating checkpoint inhibitors induced adverse events |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3920970T3 true DK3920970T3 (da) | 2023-01-23 |
Family
ID=65494072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20702304.5T DK3920970T3 (da) | 2019-02-04 | 2020-02-03 | Fremgangsmåde til behandling af utilsigtede hændelser induceret af checkpoint-hæmmere |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220125880A1 (da) |
| EP (1) | EP3920970B1 (da) |
| CA (1) | CA3128425A1 (da) |
| DK (1) | DK3920970T3 (da) |
| ES (1) | ES2935265T3 (da) |
| FI (1) | FI3920970T3 (da) |
| PL (1) | PL3920970T3 (da) |
| PT (1) | PT3920970T (da) |
| WO (1) | WO2020161045A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2935265T3 (es) | 2019-02-04 | 2023-03-03 | Hopitaux Paris Assist Publique | Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| CA2534474C (en) | 2003-08-04 | 2014-09-23 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| MX2015000237A (es) | 2012-06-27 | 2015-08-14 | Orban Biotech Llc | Proteinas de fusion ctla4 para el tratamiento de la diabetes. |
| CN116942793A (zh) | 2016-09-19 | 2023-10-27 | 昂科医药 | Cd80和cd86结合蛋白组合物及其用途 |
| ES2935265T3 (es) | 2019-02-04 | 2023-03-03 | Hopitaux Paris Assist Publique | Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control |
-
2020
- 2020-02-03 ES ES20702304T patent/ES2935265T3/es active Active
- 2020-02-03 PT PT207023045T patent/PT3920970T/pt unknown
- 2020-02-03 CA CA3128425A patent/CA3128425A1/en active Pending
- 2020-02-03 EP EP20702304.5A patent/EP3920970B1/en active Active
- 2020-02-03 PL PL20702304.5T patent/PL3920970T3/pl unknown
- 2020-02-03 WO PCT/EP2020/052554 patent/WO2020161045A1/en unknown
- 2020-02-03 FI FIEP20702304.5T patent/FI3920970T3/fi active
- 2020-02-03 DK DK20702304.5T patent/DK3920970T3/da active
- 2020-02-03 US US17/427,698 patent/US20220125880A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2935265T3 (es) | 2023-03-03 |
| FI3920970T3 (fi) | 2023-01-31 |
| EP3920970A1 (en) | 2021-12-15 |
| CA3128425A1 (en) | 2020-08-13 |
| WO2020161045A1 (en) | 2020-08-13 |
| PT3920970T (pt) | 2023-01-05 |
| PL3920970T3 (pl) | 2023-03-13 |
| EP3920970B1 (en) | 2022-11-23 |
| US20220125880A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3490398T3 (da) | Fremgangsmåde til anvendelse af et sæt vippeextensions | |
| DK3753185T3 (da) | Effektiv MAC-CE-angivelse af rumlig relation for semi-persistent SRS | |
| DK3555070T3 (da) | Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3642374T3 (da) | Fremgangsmåde til ekstraktion af lithiumforbindelse(r) | |
| DK3513617T3 (da) | Håndtering af PDCP under genetablering af forbindelse | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3458448T3 (da) | Fasn-inhibitorer til anvendelse til behandling af non-alkoholisk steatohepatitis | |
| DK3402401T3 (da) | Fremgangsmåde til bestemmelse af effektiviteten af en kompressionsbandage | |
| DK3822049T3 (da) | System til opsamling af elementer | |
| DK3920970T3 (da) | Fremgangsmåde til behandling af utilsigtede hændelser induceret af checkpoint-hæmmere | |
| DK3833665T3 (da) | Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser | |
| DK3286317T3 (da) | Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi | |
| MD3680243T2 (ro) | Compus pentaciclic | |
| DK3543405T3 (da) | Fremgangsmåde og indretning til behandling af jord | |
| DK3463328T3 (da) | Seladelpar til behandling af primær biliær cholangitis | |
| DK3765440T3 (da) | Fremgangsmåde til fremstilling af n-alkyl-nitratoethylnitraminer | |
| DK3756455T3 (da) | Fremgangsmåde og anordning til fremstilling af krydderost | |
| DK3856928T3 (da) | Fremgangsmåde til karakterisering af modifikationer forårsaget af anvendelsen af designernukleaser | |
| DK3684075T3 (da) | Systemer og metoder til accelerometerbaseret optimering af behandling udført af et høreapparat | |
| DK3737678T3 (da) | Fremgangsmåde til fremstilling af disubstituerede diaryloxybenzoheterodiazolforbindelser | |
| DK3743064T3 (da) | Behandling af proteinuri | |
| DK3725786T3 (da) | KRYSTALLINSK FORM OG SALTFORM AF TGF-ßRI INHIBITOR OG FORBEREDELSESMETODE FOR DETTE | |
| DK3543400T3 (da) | Fremgangsmåde til fremstilling af et jordstabiliseringsunderlag | |
| DK3656199T3 (da) | Fremgangsmåde til verifikation af måleværdier | |
| DK4125911T3 (da) | Obicetrapib til behandling af demens |